header
The pathology of GPP

THE PATHOLOGY OF GPP

THE IL-36 PATHWAY PLAYS A KEY ROLE IN THE PATHOGENESIS OF GPP1

The IL-36 pathway is regulated by the interplay between IL-36 agonists and antagonists to ensure a balanced immune response.2,3 When
IL-36 is overexpressed or the IL-36Ra is not functioning properly, excessive inflammation results.4

DYSREGULATED IL-36R SIGNALING LEADS TO A NEUTROPHILIC INFLAMMATORY RESPONSE AND THE DEVELOPMENT OF STERILE PUSTULES, A DISTINCT GPP CHARACTERISTIC5-7

IL-36 is a member of the IL-1 family of cytokines. Although both IL-1 and IL-36 act as drivers of the autoinflammatory responses involved in generalized pustular psoriasis (GPP), evidence suggests that IL-1 in GPP is not central and probably intervenes in a positive feedback loop induced by IL-36.8

SEE HOW THE IL-36 PATHWAY WORKS

SEE HOW GPP CAN IMPACT PATIENTS' LIVES9

LEARN MORE
How GPP can impact patients' lives

IL-1=interleukin-1; IL-36=interleukin-36; IL-36Ra=interleukin-36 receptor antagonist; IL-RAcP=interleukin-1 receptor accessory protein; TIR=toll/interleukin-1 receptor.

REFERENCES

  1. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120. doi:10.1016/j.jaci.2016.08.056

  2. Bassoy EY, Towne JE, Gabay C. Regulation and function of interleukin-36 cytokines. Immunol Rev. 2018;281(1):169-178. doi:10.1111/imr.12610

  3. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428-2437. doi:10.1038/jid.2011.234

  4. Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98(1):5-13. doi:10.2340/00015555-2808

  5. Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol. 2015;97(4): 645-652. doi:10.1189/jlb.3RI1014-495R

  6. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(77):620-628. doi:10.1056/NEJMoa1013068

  7. Navarini AA, Burden AD, Capon F, et al; for the ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. doi:10.1111/jdv.14386

  8. Iznardo H, Puig L. The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert Rev Clin Immunol. 2021;17(2):187-199. doi:10.1080/1744666X.2021.1886081

  9. Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. doi:10.1080/1744666X.2019.1708193